Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Company Overview

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.81 to $2.24
• 52-Week Range: N/A
• Volume: 2,579 shs
• Average Volume: 162,968 shs
• Market Capitalization: $8.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REXN Stock Analysis - Frequently Asked Questions

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.34.

When did Rexahn Pharmaceuticals' stock split?

Rexahn Pharmaceuticals's stock reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

• Last Earnings: 8/07/2019
• Today: 5/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:REXN
• CIK: 1228627
• Web: www.rexahn.com
• Phone: (248) 681-9815
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,640,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -72.60%
• Return on Assets: -55.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.37
• Quick Ratio: 3.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.48 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,483,000
• Free Float: N/A
• Market Cap: $8.11 million
• Optionable: Optionable
• Beta: 0.98